UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):

March 29, 2021

Immunome, Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-39580		77-0694340
(state or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

665 Stockton Drive, Suite 300 Exton, Pennsylvania		19341
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (610) 321-3700

Not applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol		Name of each exchange on which registered
Common Stock, $0.0001 par value per share		IMNM		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 7.01 Regulation FD Disclosure.

On March 29, 2021, Immunome, Inc. (the “Company”) will post a presentation to its website that may be used by the Company from time to time in meetings with investors, analysts, collaborators, vendors or other third parties. A copy of the presentation is furnished as Exhibit 99.1.

The information in this Item 7.01, including the attached exhibit, is furnished solely pursuant to Item 7.01 of Form 8-K. Consequently, such information is not deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that section. Further, the information in this Item 7.01, including the exhibit, shall not be deemed to be incorporated by reference into the filings of the registrant under the Securities Act of 1933.

Cautionary Statement Regarding Forward-Looking Information

This current report on Form 8-K contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than those of historical fact in this presentation and accompanying oral commentary are forward-looking statements. Forward-looking statements may be identified by terminology such as “believe,” “anticipate,” “plan,” “may,” “intend,” “will,” “should,” “expect,” “estimate,” “potential” and “continue” and similar expressions, including the negative of these words, but not all forward-looking statements contain these words. Forward-looking statements include, but are not limited to, statements regarding our financial position, strategy, business plans; expectations regarding the timing, progress and achievement of our research and development activities, preclinical studies, any clinical trials and regulatory filings and submissions; our ability to secure and execute on partnerships and collaborations; our expectations regarding the activity and therapeutic potential of our current and future product candidates; our achievement of corporate milestones and the implementation of our business model; and the adequacy of our financial resources to support our operations. Forward-looking statements are based on our current expectations and are subject to inherent uncertainties, risks and assumptions applicable to Immunome and our industry in general that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, those risks and uncertainties associated with our ability to execute on our strategy, including with respect to the timing of our R&D efforts, regulatory filings, initiation of clinical studies and other anticipated milestones; the timing and effectiveness of any antibody therapeutics which may be developed by us; our ability to finance our operations; the impact of the COVID-19 pandemic on our business, operations, strategy, goals and anticipated milestones; and the additional risks and uncertainties set forth more fully under the caption “Risk Factors” in our Annual Report on Form 10-K filed on March 25, 2021 with the Securities and Exchange Commission (SEC) and elsewhere in our filings and reports with the SEC. These risks, uncertainties and other factors may cause our actual results to differ materially and adversely from what is contained in (or may be implied from) any forward-looking statements. Forward-looking statements speak as of the date they are made, and the Company undertakes no obligation to update them except as may be required under applicable law.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description

99.1		Presentation dated March 29, 2021 (furnished herewith)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	IMMUNOME, INC.

	By:	/s/ Purnanand D. Sarma
		Purnanand D. Sarma, Ph.D. President and Chief Executive Officer

Dated: March 29, 2021

Exhibit 99.1

Copyright © 2021 Immunome, Inc. All rights reserved. Harnessing the Human Memory B Cell Response To Develop Antibody - Based Therapeutics March 29, 2021 Immunome, Inc. 665 Stockton Drive, Suite 300 | Exton, PA 19341 610.321.3700 | www.immunome.com

2 Copyright © 2021 Immunome, Inc. All rights reserved. Forward Looking Statements This presentation includes certain disclosures that contain “forward - looking statements” intended to qualify for the “safe harbor” from liability established by the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, express or implied statements regarding our beliefs and expectations regarding the advancement of our oncology and COVID - 19 therapeutic antibody programs, execution of our clinical and strategic plans, anticipated upcoming milestones for IMM - BCP - 01 and IMM - ONC - 01, including expectations regarding therapeutic potential and benefits thereof, and IND filings. Forward - looking statements may be identified by the words “anticipate,” believe,” “estimate,” “expect,” “intend,” “plan,” “project,” “may,” “will,” “could,” “should,” “seek,” “potential” and similar expressions. Forward - looking statements are based on our current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, those risks and uncertainties associated with: the impact of the COVID - 19 pandemic on our business, operations, strategy, goals and anticipated milestones; our ability to execute on our strategy including with respect to the timing of our R&D efforts, IND filings, initiation of clinical studies and other anticipated milestones; the timing and effectiveness of any antibody therapeutics which may be developed by us; our ability to fund operations; and the additional risks and uncertainties set forth more fully under the caption “Risk Factors” in our Annual Report on Form 10 - K filed with the United States Securities and Exchange Commission (SEC) on March 25, 2021, and elsewhere in our filings and reports with the SEC. Forward - looking statements contained in this announcement are made as of this date, and we undertake no duty to publicly update or revise any forward looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable law. This document may contain product names, trade names, trademarks and service marks of the Company and of other organizations, of which are the properties of their respective owners. Statements that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based on information available to us as of the date of this presentation. While we believe that information provides a reasonable basis for these statements, that information may be limited or incomplete. Our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all relevant information. In this presentation and oral commentary, we may discuss our current and potential future product candidates that have not yet been approved for marketing by the U.S. Food and Drug Administration. No representation is made as to the safety or effectiveness of these current or potential future product candidates for the use for which such product candidates are being studied. This presentation does not constitute an offering of securities of any kind.

Copyright © 2021 Immunome, Inc. All rights reserved. 3 Immunome Overview Harness the Power of the Most Educated Components of the Human Immune System • Rapid and unbiased interrogation of memory B cells to identify novel targets and antibodies directed at them • Output has potential to advance 1 - 2 candidates into IND - enabling studies per year • Broad applicability across therapeutic areas allows for partnering opportunities Proprietary Discovery Engine Oncology (IMM - ONC - 01) Infectious Diseases (IMM - BCP - 01) • First - in - class fully human antibody targeting IL - 38 protein • IND filing anticipated in 2H 2021 • Growing portfolio of over 50 novel antibody - target pairs for additional therapeutic candidates • COVID - 19 Multi - Antibody Cocktail targeting SARS - CoV - 2 • IND filing anticipated in 1H 2021 • $13.3M contract from U.S. Department of Defense to fund IMM - BCP - 01 • Rapid B cell interrogation potentially enables rapid response to future threats

Copyright © 2021 Immunome, Inc. All rights reserved. 4 The Power of Memory B Cells Immunome’s Discovery Engine Sees Disease Through the Lens of the Human Memory B Cell • Memory B cells remember specific antigens and allow for a rapid antibody response 1 • The antibodies that these cells produce are a primary component of the body’s response to a number of diseases: » In cancer, the presence of memory B cells in tumors is associated with favorable outcomes in response to I/O therapy 2 - 4 » In infectious disease, these cells produce the high - affinity antibodies that are responsible for fighting disease Memory B cells are the most educated component of the immune response 1. B Cell Localization and Migration in Health and Disease, Anja E. Hauser, Uta E. Höpken , in Molecular Biology of B Cells (Second Edition), 2015 2. Helmink et al Nature 577, 549 - 555; 2020 3. Petiprezet al Nature 577, 556 - 560; 2020 4. Cabrita et al Nature 577 ,561 - 565; 2020

Copyright © 2021 Immunome, Inc. All rights reserved. 5 Immunome Discovery Engine Unbiased Interrogation of Memory B Cells Yields a Deep and Diverse Set of Potential Therapies • Primary human memory B cells immortalized as stable hybridomas - thousands of hybridomas per patient • High - throughput screening - 20,000 antibodies per array • Deep interrogation of patient response to generate “hits,” high conversion rate from hits to targets • Directly isolates potential therapeutic antibodies for use in oncology and infectious diseases Immunome Discovery Engine Differentiators Antibody Screening Deep, multiplexed interrogation of patient memory B cell responses Patient Response Capture memory B cells from cancer or infectious disease patients Antibody Validation Definitive target identification and characterization of antibody / target interactions Discovery Engine Output Unique therapeutic antibody / antigen target pairs Patient Sampling Ongoing access to new and diverse patient memory B cells to feed the engine

Copyright © 2021 Immunome, Inc. All rights reserved. 6 Using the B Cell Lens Discovery Engine Appears to Reveal Rare and Novel Targets • Rare, broadly conserved epitopes in infectious disease » Antibodies binding to Spike protein epitopes conserved across multiple SARS - CoV - 2 variants and even SARS - CoV - 1 » Broadly neutralizing antibodies against multiple polio strains . Currently used by WHO/FDA in universal ELISA for quantification of polio vaccine 1 » Anti - A b 40 antibodies, that appear to bind a structural epitope conserved across amyloids from bacterial biofilms to humans 2,3 • Novel Cancer Biology Insights » Functional target clusters (e.g., exosome biology) » Checkpoint of the Innate Immune System Unique Antibodies Enable Access to Fundamental Biology 1. Kouiavskai, et al 2020 2. Tursi et al Nature Commun, 2020 3. Levites et al J Neuroscience, 2015

7 Copyright © 2021 Immunome, Inc. All rights reserved. Immunome Pipeline & Anticipated Milestones ONCOLOGY TARGET PRODUCT CANDIDATE DESCRIPTION DISCOVERY PRECLINICAL NEXT MILESTONE IMM - ONC - 01 IL - 38 I/O, Novel Checkpoint Anticipate IND filing 2H 2021 ANTI - INFECTIVES TARGET PRODUCT CANDIDATE DESCRIPTION DISCOVERY PRECLINICAL NEXT MILESTONE IMM - BCP - 01 Multiple SARS - CoV - 2 Antigens Antibody cocktail Anticipate IND filing late Q2/ early Q3 2021

Copyright © 2021 Immunome, Inc. All rights reserved. 9 Untapped Potential in Immuno - Oncology Current Therapies are Based on Limited Understanding of the Diversity and Complexity of Human Tumors T cell targeted immuno - oncology approaches have redefined the way we treat cancer However, large numbers of patients cannot be treated using T cell - targeted approaches Tumors subvert immunity through multiple mechanisms, often simultaneously T cell compartment is only one component of a complex immune response to tumors B cells offers untapped biology and a new approach to advancing a novel wave of targets and therapies

Copyright © 2021 Immunome, Inc. All rights reserved. 10 Immunome’s Discovery & Output Memory B Cells Interrogation Reveals Target Rich “Clusters” • Common biological processes that may have disease relevance, such as exosome control of the tumor microenvironment 1 - 2 • Novel immune checkpoints that serve as functional, tumor - derived inhibitors of immunity Provides critical insights into cancer biology such as: 1. Adv Clin Chem. 2016;74:103 - 41.DOI: 10.1016/bs.acc.2015.12.005 2. Mol Cancer. 2019 Oct 23;18(1):146. doi : 10.1186/s12943 - 019 - 1074 - 3 3. Including some commercially - validated targets such as ERBB2 Target Cluster 2 Target Cluster 5 Target Cluster 1 Target Cluster 3 Target Cluster 4 Target Cluster 6 13 22 22 2 10 2 A Highly Productive Platform; Outputs To Date: 300,000 hybridomas | 1,300 hits 50+ antibody / antigen pairs 3

Copyright © 2021 Immunome, Inc. All rights reserved. 11 IL - 38: A Novel Oncology Target IL - 38 Appears to Dampen Innate Anti - Tumor Immunity • IL - 38 is an IL - 1 cytokine family member, but most closely resembles the natural antagonists of the family (IL - 1Ra and IL - 36a) • IL - 38 inhibits infiltration & pro - inflammatory activity of innate immune cells (e.g., M Φ, γδ T cells, DCs) • IL - 38 inhibits innate immune responses by dendritic cell precursors, macrophages Blocking IL - 38 is expected to boost anti - tumor immunity 1. Crystal Structure: Research Collaboratory for Structural Bioinformatics Protein Data Bank (rcsb.org): PDB 5BOW Typical Inflammatory Anti - tumor Response PD - 1/PD - L1 IL - 38 1

Copyright © 2021 Immunome, Inc. All rights reserved. 12 IL - 38 Expression in Solid Tumors IL - 38 is Over - Expressed in Multiple Tumors of High Unmet Medical Need, and Associated with Reduced Immune Cell Infiltration IL - 38 is over - expressed in multiple tumors of high unmet medical need Inverse relationship between IL - 38 expression and immune cell infiltration in tumors Head & Neck Lung, Squamous Esophagus Cervix Prostate Bladder Skin Lung, Adeno 23% 53% 41% 48% 25% 14% 30% 9% Immunome analysis of the Cancer Genome Atlas (TCGA) data from Firehouse Legacy dataset T Cells Macrophages

Copyright © 2021 Immunome, Inc. All rights reserved. 14 IL - 38 & Innate Immunity IL - 38 Inhibits Myeloid Cell Activation In Vitro Blocks IL - 36 mediated inflammatory signals IL - 36 γ induced IL - 8 in PBMCs PNAS 2012;109 (8):3001 Suppresses Dendritic Cell Function Inhibits macrophage inflammatory response Reduction of DC Stimulatory Capacity J. Cell Mol. Med. 2020;24 (1):371 LPS induced RNA expression in THP - 1 Immunome Data

Copyright © 2021 Immunome, Inc. All rights reserved. 15 IMM - ONC - 01 Blocking IL - 38 Leads to Tumor Control in Two Different Tumor Models Demonstration of Anti - Tumor Activity (B16F10 Model) Induction of Anti - Tumor Memory (EMT6 Model) • Immunologically cold tumor model • IMM - ONC - 01 equivalent to best in class I/O (anti - CTLA4) in this model • IMM - ONC - 01 vs anti - mCTLA4 • ~40% response rate upon treatment with IMM - ONC - 01 ab • Animals with complete cures resistant to tumor re - challenge • Strongly suggests immunological memory • Consistent with proposed MOA 5 10 15 20 25 0 500 1000 Study Day M e a n T u m o r V o l u m e ± S E M ( m m 3 ) 1333-103G EMT6 Re-challenge: Mean TV Untreated control (n=5) Anti-CTLA4 (n=4) CD1M3 (n=4) Vehicle control Anti - mCTLA4 IMM - ONC - 01 Vehicle control Anti - mCTLA4 IMM - ONC - 01

Copyright © 2021 Immunome, Inc. All rights reserved. 16 IMM - ONC - 01 Program Summary Modulating Innate Anti - Tumor Immunity • IL - 38 is a novel checkpoint in the innate immune system » Target of an antibody isolated from the memory B cells of a patient with head and neck cancer • Targeting IL - 38 using IMM - ONC - 01 can boost anti - tumor immunity » Potential indications include multiple cancers with high unmet medical need • Currently in IND - enabling studies • IND filing anticipated in 2H 2021 IMM - ONC - 01 is a novel antibody candidate targeting IL - 38 huIgG (PDB 1HZH) 1 1. Crystal Structure: Research Collaboratory for Structural Bioinformatics Protein Data Bank (rcsb.org): PDB 1HZH

Copyright © 2021 Immunome, Inc. All rights reserved. 18 Ongoing Need for COVID Therapies Our Hypothesis: Natural Viral Mutation, Selection Pressure of Interventions Expected to Drive Emergence of New Variants and Need for Novel Therapies Evolving SARS - CoV - 2 Escape Mutants • Efficacy of vaccines & therapeutics negatively impacted by the emergence of variants worldwide » UK (B.1.1.7), Brazilian (P.1), and S. African (B.1.351) are of particular concern • Immunome’s approach is aimed at overcoming the effects of mutational drift » Target broadly conserved epitopes on the Spike protein » Mechanisms beyond Spike potentially increase viral clearance and reduce susceptibility to drift 1. Fig. adapted from: Cell (2021), doi : https://doi.org/10.1016/j.cell.2021.03.013 Pseudovirus neutralization by vaccinee sera 1 UK Brazil S Africa

Copyright © 2021 Immunome, Inc. All rights reserved. 19 IMM - BCP - 01 Therapeutic Antibody Cocktail Against Multiple SARS - CoV - 2 Antigens Collaboration with U.S. DoD awarded, up to $13.3M in funding Select convalescent patients with strong anti - viral titer Antibody cocktail for potential prophylaxis and treatment Deep repertoire screening against multiple viral proteins Collect convalescent blood and isolate memory B cells Produce antibody mixture (up to 6 Abs) using recombinant manufacture Screen for anti - viral antibodies Discovery engine enables rapid isolation of antibodies against SARS - CoV - 2 and potentially other infectious agents

Copyright © 2021 Immunome, Inc. All rights reserved. 20 IMM - BCP - 01 Hypothesis Neutralizing Antibody Therapeutics vs. Immunome’s Antibody Cocktail Approach Neutralizing Antibodies • Target single protein • New strains may readily evade IMM - BCP - 01 Profile ▪ Multiple antibodies against diverse viral antigens ▪ Approach can be exploited as a rapid response platform for use against other emerging infections IMM - BCP - 01 • Targets multiple viral epitopes • Broader coverage across multiple variants Virus Isolate 1 Virus Isolate 2

Copyright © 2021 Immunome, Inc. All rights reserved. 21 B Cell Interrogation of Super - Responders “Super Responders” Mount Robust Immune Response Against SARS - CoV - 2 More than 50% of the antibodies identified bind to SARS - CoV - 2 proteins other than Spike • Open Reading Frame - coded (ORF) proteins and nucleocapsid represent the most prevalent non - Spike targets • Antibody response to neutralizing and non - neutralizing epitopes on Spike protein are committed to B cell memory • Response appears to extend beyond Immunoglobulin G (IgG), comprising of affinity - matured antibodies with specialized function (IgA and IgM) https://www.biorxiv.org/content/10.1101/2021.01.27.428534v1).

Copyright © 2021 Immunome, Inc. All rights reserved. 22 Anti - Spike Antibodies Super Responders Express Broadly Neutralizing Anti - Spike SARS - CoV - 2 Antibodies • Antibodies identified against non - overlapping regions of SARS - CoV - 2 Spike protein » Includes regions containing critical mutational variants • Certain antibodies also neutralize pseudoviruses expressing the Spike protein of UK (B.1.1.7) and South African (B.1.351) variants • Our discovery engine has identified antibodies that bind to conserved epitopes of SARS - CoV - 1 and SARS - CoV - 2 Spike SARS - CoV2 super responders mount a robust immune response Multiple antibodies Activity against variants Variant 2 Variant 1

Copyright © 2021 Immunome, Inc. All rights reserved. 23 IMM - BCP - 01 Program Summary Antibody Cocktail Targeting the Multiple SARS - CoV - 2 Antigens • Patients mount immune response against multiple SARS - CoV - 2 antigens • Certain anti - Spike antibodies neutralize multiple SARS - CoV - 2 variants • Non - Spike directed antibodies are being evaluated for synergy • Contract Development and Manufacturing Organization has been selected • Planned IND filing in late 2Q/early 3Q 2021 IMM - BCP - 01: potential as a therapy and prophylaxis for SARS - CoV - 2

25 Copyright © 2021 Immunome, Inc. All rights reserved. ONCOLOGY TARGET PRODUCT CANDIDATE DESCRIPTION DISCOVERY PRECLINICAL NEXT MILESTONE IMM - ONC - 01 IL - 38 I/O, Novel Checkpoint Anticipate IND filing 2H 2021 ANTI - INFECTIVES TARGET PRODUCT CANDIDATE DESCRIPTION DISCOVERY PRECLINICAL NEXT MILESTONE IMM - BCP - 01 Multiple SARS - CoV - 2 proteins Antibody cocktail Anticipate IND filing late Q2/ early Q3 2021 Immunome Pipeline & Anticipated Milestones

Copyright © 2021 Immunome, Inc. All rights reserved. 26 Immunome Harnessing the Power of the Most - educated Components of the Human Immune System • Proprietary Discovery Engine enables the interrogation of human memory B cells to simultaneously identify potential first - in - class antibody therapeutics and novel antigen targets » Unbiased, broad, deep and fast • Two lead preclinical programs in oncology and infectious disease, with INDs expected in 2021 » IMM - ONC - 01: Antibody against IL - 38, a novel innate immune checkpoint IMM - BCP - 01: Antibody cocktail against diverse SARS - CoV - 2 antigens • The Discovery Engine efficiency potentially allows 1 - 2 programs IND - enabling studies per year » Over 1,300 oncology hits; 50+ targets » Significant potential as a rapid response platform against future infectious agents

Copyright © 2021 Immunome, Inc. All rights reserved. 28 Management Team Michael Morin, PhD Chief Science Officer Oversaw cancer, immunology and anti - bacterial drug discovery Dennis Giesing , PhD Chief Development Officer Jillian DiMuzio Senior Director, HTS & Automation Ben Harman, PhD Director, Target Identification Leadership with experience in the fields of oncology, infectious disease, drug discovery and leveraging platform technologies for drug development Purnanand Sarma, PhD President & CEO Former CEO, TARIS Biomedical; VP & GM, Cephalon; VP & Managing Director, Nektar Therapeutics Matthew Robinson, PhD SVP, Research & Development Fang Shen, PhD VP, Research & Translational Biology Dennis Dong, PhD VP, Product Development Pavel Nikitin, PhD Director, Antibody Engineering Lifang Liang, PhD Head of Anti - Infectives & Government Liaison Sandra Stoneman, Esq. Chief Legal Officer Diane Marcou Chief Financial Officer

Copyright © 2021 Immunome, Inc. All rights reserved. 29 Scientific Advisory Board Scott Dessain, MD, PhD Chair, Founder Joseph and Ray Gordon Chair of Clinical Oncology and Research at Lankenau Institute for Medical Research George Prendergast, PhD Cancer Biology Former Editor of Cancer Research President and CEO of Lankenau Institute for Medical Research William Strohl, PhD Antibody Engineering & GMP Formerly Centocor; Biologics Lead at J&J Anthony Tolcher, MD, FRCPC Early Clinical Development NEXT Oncology, San Antonio Medical Center Louis Weiner, MD Immuno - Oncology Director, Georgetown Lombardi Comprehensive Cancer Center and Director, MedStar Georgetown Cancer Institute Michael Diamond , MD, PhD Washington University School of Medicine The Herbert S. Gasser Professor of Medicine and Professor of Molecular Biology Pathology and Immunology Associate Director, for the Andrew M. and Jane M. Bursky Center for Human Immunology and Immunotherapy Programs Jeffery Henderson , MD, PhD Washington University Associate Professor of Medicine and Molecular Biology M ember, National Convalescent Plasma Project (CCPP19) Shmuel Shoham , MD Johns Hopkins University School of Medicine Associate Professor of Medicine M ember, National Convalescent Plasma Project (CCPP19) Susan Weiss , PhD University of Pennsylvania Perelman School of Medicine Professor and Vice Chair, Department of Microbiology Co - Director, Penn Center for Research on Coronaviruses and Other Emerging Pathogens Oncology COVID - 19

Copyright © 2021 Immunome, Inc. All rights reserved. 30 Board of Directors Michael Rapp, Chairman Managing Partner, Broadband Capital Investments, LLC Richard Baron Formerly Chief Financial Officer, Zynerba Pharmaceuticals John LaMattina, PhD Formerly President, Pfizer Global Research & Development Michael Lefenfeld President and CEO, Cyanco International Co - founder of SiGNa Chemistry Purnanand Sarma, PhD President & CEO, Immunome Inc. Philip Wagenheim Managing Partner, Broadband Capital Partners, LLC Michael Widlitz, MD Formerly of clinical development & medical affairs at Pfizer